Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival ...

Bemarituzumab, an investigational first-in-class monoclonal antibody, may extend overall survival in patients with FGFR2b-positive gastric cancer, but the benefit wanes significantly with time, ...

Long-term use of common anti-acid medications, known as proton pump inhibitors (PPIs), may not increase the risk of stomach cancer, a new study suggests, potentially offering reassurance to millions ...

HLX22 received orphan drug designation, offering incentives like tax credits and market exclusivity to accelerate development for gastric cancer treatment. Phase 2 trial results showed HLX22 improved ...

GA, UNITED STATES, February 20, 2026 /EINPresswire.com/ — A next-generation antibody–drug conjugate has transformed treatment for HER2-positive gastric cancer ...

The potential link between use of proton pump inhibitors and gastric cancer has been an ongoing controversial subject since the drugs entered the market in the late 1980s. Long-term use of proton pump ...

Tevimbra/Ziihera as a first-line treatment for advanced cancers of the stomach, gastroesophageal junction, and esophagus. The ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the drug the title of the first and only immunotherapy marketed to treat ...

Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. This is an ASCO Meeting Abstract ...

The Scottish Medicines Consortium (SMC) has approved zolbetuximab (Vyloy, Astellas Pharma) for treating advanced gastric and gastro-oesophageal junction (GEJ) cancer in combination with ...

Brittany Svehlak was diagnosed with stomach cancer in 2024, but just two years later, her health took another turn for the ...